Retrospective cohort study of Methotrexate use in the treatment of pediatric Crohn's disease

Whitney Sunseri, Jeffrey S. Hyams, Trudy Lerer, David R. Mack, Anne M. Griffiths, Anthony R. Otley, Joel R. Rosh, Ryan Carvalho, Andrew B. Grossman, Jose Cabrera, Marian Pfefferkorn, James Rick, Neal S. Leleiko, Meredith C. Hitch, Maria Oliva-Hemker, Shehzad A. Saeed, Michael Kappelman, James Markowitz, David J. Keljo

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Background: Methotrexate (MTX) use as an alternative to thiopurines in the treatment of Crohn's disease (CD) in children is increasing. This study was undertaken to assess safety and efficacy of MTX in children with CD. Methods: Patients treated with MTX with a minimum of 1-year follow-up were identified in the Pediatric IBD Collaborative Research Group Registry, a prospective inception cohort study started in 2002. The clinical efficacy and safety of MTX were analyzed retrospectively. Results: Two hundred ninety patients treated with MTX were identified. One hundred seventy-two patients received at least 3 months of MTX without thiopurine or biologicals and had ≥ 1 year of follow-up. Eighty-one of 172 patients (47%) received MTX as first immunomodulator (IMM), of which 22 (27%) achieved ≥ 12 months of sustained clinical remission without surgery, thiopurine, biologicals, or corticosteroids. Those receiving MTX as second IMM achieved similar remission rate (35%, P = not significant). Fourteen percent received MTX as first IMM in 2002 and 60% in 2010 (P = 0.005). Disease location did not affect outcomes. MTX doses were equivalent in both groups. Fifteen percent of patients developed an alanine aminotransferase > 60 international units/liter and 12% developed a white blood cell < 4000 cells per microliter while on MTX. Only 4% of these discontinued MTX completely. A small group of 6 centers, which contributed only about one-third of patients with CD in the registry, contributed nearly two-thirds of the patients receiving MTX (P < 0.001). Conclusions: MTX use as first choice IMM is increasing in pediatric CD. MTX provided sustained clinical remission in nearly one-third of patients with minimal toxicity. There is large center-to-center variability in its use.

Original languageEnglish
Pages (from-to)1341-1345
Number of pages5
JournalInflammatory Bowel Diseases
Volume20
Issue number8
DOIs
StatePublished - 2014

Fingerprint

Methotrexate
Cohort Studies
Retrospective Studies
Immunologic Factors
Therapeutics
Crohn Disease
Pediatric Crohn's disease
Registries
Safety
Alanine Transaminase
Adrenal Cortex Hormones
Leukocytes

Keywords

  • Crohn's disease
  • Hepatosplenic T-cell lymphoma
  • Inflammatory bowel disease
  • Methotrexate
  • Pediatrics

ASJC Scopus subject areas

  • Gastroenterology
  • Immunology and Allergy
  • Medicine(all)

Cite this

Sunseri, W., Hyams, J. S., Lerer, T., Mack, D. R., Griffiths, A. M., Otley, A. R., ... Keljo, D. J. (2014). Retrospective cohort study of Methotrexate use in the treatment of pediatric Crohn's disease. Inflammatory Bowel Diseases, 20(8), 1341-1345. https://doi.org/10.1097/MIB.0000000000000102

Retrospective cohort study of Methotrexate use in the treatment of pediatric Crohn's disease. / Sunseri, Whitney; Hyams, Jeffrey S.; Lerer, Trudy; Mack, David R.; Griffiths, Anne M.; Otley, Anthony R.; Rosh, Joel R.; Carvalho, Ryan; Grossman, Andrew B.; Cabrera, Jose; Pfefferkorn, Marian; Rick, James; Leleiko, Neal S.; Hitch, Meredith C.; Oliva-Hemker, Maria; Saeed, Shehzad A.; Kappelman, Michael; Markowitz, James; Keljo, David J.

In: Inflammatory Bowel Diseases, Vol. 20, No. 8, 2014, p. 1341-1345.

Research output: Contribution to journalArticle

Sunseri, W, Hyams, JS, Lerer, T, Mack, DR, Griffiths, AM, Otley, AR, Rosh, JR, Carvalho, R, Grossman, AB, Cabrera, J, Pfefferkorn, M, Rick, J, Leleiko, NS, Hitch, MC, Oliva-Hemker, M, Saeed, SA, Kappelman, M, Markowitz, J & Keljo, DJ 2014, 'Retrospective cohort study of Methotrexate use in the treatment of pediatric Crohn's disease', Inflammatory Bowel Diseases, vol. 20, no. 8, pp. 1341-1345. https://doi.org/10.1097/MIB.0000000000000102
Sunseri, Whitney ; Hyams, Jeffrey S. ; Lerer, Trudy ; Mack, David R. ; Griffiths, Anne M. ; Otley, Anthony R. ; Rosh, Joel R. ; Carvalho, Ryan ; Grossman, Andrew B. ; Cabrera, Jose ; Pfefferkorn, Marian ; Rick, James ; Leleiko, Neal S. ; Hitch, Meredith C. ; Oliva-Hemker, Maria ; Saeed, Shehzad A. ; Kappelman, Michael ; Markowitz, James ; Keljo, David J. / Retrospective cohort study of Methotrexate use in the treatment of pediatric Crohn's disease. In: Inflammatory Bowel Diseases. 2014 ; Vol. 20, No. 8. pp. 1341-1345.
@article{6c75210696214e6cba3c82d9ddc1d594,
title = "Retrospective cohort study of Methotrexate use in the treatment of pediatric Crohn's disease",
abstract = "Background: Methotrexate (MTX) use as an alternative to thiopurines in the treatment of Crohn's disease (CD) in children is increasing. This study was undertaken to assess safety and efficacy of MTX in children with CD. Methods: Patients treated with MTX with a minimum of 1-year follow-up were identified in the Pediatric IBD Collaborative Research Group Registry, a prospective inception cohort study started in 2002. The clinical efficacy and safety of MTX were analyzed retrospectively. Results: Two hundred ninety patients treated with MTX were identified. One hundred seventy-two patients received at least 3 months of MTX without thiopurine or biologicals and had ≥ 1 year of follow-up. Eighty-one of 172 patients (47{\%}) received MTX as first immunomodulator (IMM), of which 22 (27{\%}) achieved ≥ 12 months of sustained clinical remission without surgery, thiopurine, biologicals, or corticosteroids. Those receiving MTX as second IMM achieved similar remission rate (35{\%}, P = not significant). Fourteen percent received MTX as first IMM in 2002 and 60{\%} in 2010 (P = 0.005). Disease location did not affect outcomes. MTX doses were equivalent in both groups. Fifteen percent of patients developed an alanine aminotransferase > 60 international units/liter and 12{\%} developed a white blood cell < 4000 cells per microliter while on MTX. Only 4{\%} of these discontinued MTX completely. A small group of 6 centers, which contributed only about one-third of patients with CD in the registry, contributed nearly two-thirds of the patients receiving MTX (P < 0.001). Conclusions: MTX use as first choice IMM is increasing in pediatric CD. MTX provided sustained clinical remission in nearly one-third of patients with minimal toxicity. There is large center-to-center variability in its use.",
keywords = "Crohn's disease, Hepatosplenic T-cell lymphoma, Inflammatory bowel disease, Methotrexate, Pediatrics",
author = "Whitney Sunseri and Hyams, {Jeffrey S.} and Trudy Lerer and Mack, {David R.} and Griffiths, {Anne M.} and Otley, {Anthony R.} and Rosh, {Joel R.} and Ryan Carvalho and Grossman, {Andrew B.} and Jose Cabrera and Marian Pfefferkorn and James Rick and Leleiko, {Neal S.} and Hitch, {Meredith C.} and Maria Oliva-Hemker and Saeed, {Shehzad A.} and Michael Kappelman and James Markowitz and Keljo, {David J.}",
year = "2014",
doi = "10.1097/MIB.0000000000000102",
language = "English",
volume = "20",
pages = "1341--1345",
journal = "Inflammatory Bowel Diseases",
issn = "1078-0998",
publisher = "John Wiley and Sons Inc.",
number = "8",

}

TY - JOUR

T1 - Retrospective cohort study of Methotrexate use in the treatment of pediatric Crohn's disease

AU - Sunseri, Whitney

AU - Hyams, Jeffrey S.

AU - Lerer, Trudy

AU - Mack, David R.

AU - Griffiths, Anne M.

AU - Otley, Anthony R.

AU - Rosh, Joel R.

AU - Carvalho, Ryan

AU - Grossman, Andrew B.

AU - Cabrera, Jose

AU - Pfefferkorn, Marian

AU - Rick, James

AU - Leleiko, Neal S.

AU - Hitch, Meredith C.

AU - Oliva-Hemker, Maria

AU - Saeed, Shehzad A.

AU - Kappelman, Michael

AU - Markowitz, James

AU - Keljo, David J.

PY - 2014

Y1 - 2014

N2 - Background: Methotrexate (MTX) use as an alternative to thiopurines in the treatment of Crohn's disease (CD) in children is increasing. This study was undertaken to assess safety and efficacy of MTX in children with CD. Methods: Patients treated with MTX with a minimum of 1-year follow-up were identified in the Pediatric IBD Collaborative Research Group Registry, a prospective inception cohort study started in 2002. The clinical efficacy and safety of MTX were analyzed retrospectively. Results: Two hundred ninety patients treated with MTX were identified. One hundred seventy-two patients received at least 3 months of MTX without thiopurine or biologicals and had ≥ 1 year of follow-up. Eighty-one of 172 patients (47%) received MTX as first immunomodulator (IMM), of which 22 (27%) achieved ≥ 12 months of sustained clinical remission without surgery, thiopurine, biologicals, or corticosteroids. Those receiving MTX as second IMM achieved similar remission rate (35%, P = not significant). Fourteen percent received MTX as first IMM in 2002 and 60% in 2010 (P = 0.005). Disease location did not affect outcomes. MTX doses were equivalent in both groups. Fifteen percent of patients developed an alanine aminotransferase > 60 international units/liter and 12% developed a white blood cell < 4000 cells per microliter while on MTX. Only 4% of these discontinued MTX completely. A small group of 6 centers, which contributed only about one-third of patients with CD in the registry, contributed nearly two-thirds of the patients receiving MTX (P < 0.001). Conclusions: MTX use as first choice IMM is increasing in pediatric CD. MTX provided sustained clinical remission in nearly one-third of patients with minimal toxicity. There is large center-to-center variability in its use.

AB - Background: Methotrexate (MTX) use as an alternative to thiopurines in the treatment of Crohn's disease (CD) in children is increasing. This study was undertaken to assess safety and efficacy of MTX in children with CD. Methods: Patients treated with MTX with a minimum of 1-year follow-up were identified in the Pediatric IBD Collaborative Research Group Registry, a prospective inception cohort study started in 2002. The clinical efficacy and safety of MTX were analyzed retrospectively. Results: Two hundred ninety patients treated with MTX were identified. One hundred seventy-two patients received at least 3 months of MTX without thiopurine or biologicals and had ≥ 1 year of follow-up. Eighty-one of 172 patients (47%) received MTX as first immunomodulator (IMM), of which 22 (27%) achieved ≥ 12 months of sustained clinical remission without surgery, thiopurine, biologicals, or corticosteroids. Those receiving MTX as second IMM achieved similar remission rate (35%, P = not significant). Fourteen percent received MTX as first IMM in 2002 and 60% in 2010 (P = 0.005). Disease location did not affect outcomes. MTX doses were equivalent in both groups. Fifteen percent of patients developed an alanine aminotransferase > 60 international units/liter and 12% developed a white blood cell < 4000 cells per microliter while on MTX. Only 4% of these discontinued MTX completely. A small group of 6 centers, which contributed only about one-third of patients with CD in the registry, contributed nearly two-thirds of the patients receiving MTX (P < 0.001). Conclusions: MTX use as first choice IMM is increasing in pediatric CD. MTX provided sustained clinical remission in nearly one-third of patients with minimal toxicity. There is large center-to-center variability in its use.

KW - Crohn's disease

KW - Hepatosplenic T-cell lymphoma

KW - Inflammatory bowel disease

KW - Methotrexate

KW - Pediatrics

UR - http://www.scopus.com/inward/record.url?scp=84905463638&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84905463638&partnerID=8YFLogxK

U2 - 10.1097/MIB.0000000000000102

DO - 10.1097/MIB.0000000000000102

M3 - Article

VL - 20

SP - 1341

EP - 1345

JO - Inflammatory Bowel Diseases

JF - Inflammatory Bowel Diseases

SN - 1078-0998

IS - 8

ER -